Personalized Immunotherapy

Our department is dedicated to addressing critical challenges in cancer immunotherapy, focusing on three key research areas:

• Targeted RNA Delivery: Investigating the potential of targeted RNA delivery to enhance T-cell functionality by enforcing the expression of specific transcription factors. This research aims to expand progenitor exhausted T cells, thereby improving patient response to immune checkpoint inhibitors.
• Antibody-Drug Conjugates (ADCs): Exploring the interaction between ADCs and the host immune system to understand their effects on the tumor microenvironment. We examine ADC efficacy in "cold" and "hot" tumors and seek optimal strategies to combine ADCs with immunotherapies like checkpoint blockade and mRNA vaccines.
• Monoclonal Antibodies Targeting Claudin 18.2: Unraveling the mechanisms and rationale behind targeting Claudin 18.2, a promising therapeutic approach for specific cancers.

Our department employs state-of-the-art techniques and platforms, including:

• RNA-LNP Engineering: Developing precise delivery systems to modulate gene expression in immune cells in collaboration with the mRNA Cancer Immunotherapy Division at HI-TRON.
• Immune Profiling: Using advanced flow cytometry, single-cell RNA sequencing, and imaging techniques to analyze immune-tumor interactions.
• ADC Characterization: Leveraging preclinical models and high-resolution imaging to assess ADC efficacy and mechanism of action.
• Translational Research: Partnering with clinical teams to validate laboratory findings and design trials that integrate novel therapies.